Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Arcus Biosciences (RCUS) stocks in Canada

Learn how to easily invest in Arcus Biosciences stocks.

Arcus Biosciences (RCUS) is a leading biotechnology business based in the US. It opened the day at $28.72 after a previous close of $28.75. During the day the price has varied from a low of $28.46 to a high of $29.185. The latest price was $29.07 (25 minute delay). Arcus Biosciences is listed on the NYSE and employs 236 staff. All prices are listed in US Dollars.

How to buy shares in Arcus Biosciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – RCUS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Arcus Biosciences stock price (NYSE:RCUS)

Use our graph to track the performance of RCUS stocks over time.

Arcus Biosciences shares at a glance

Information last updated 2021-07-09.
Open$28.72
High$29.19
Low$28.46
Close$29.07
Previous close$28.75
Change $0.32
Change % 1.113%
Volume 721,166
Information last updated 2022-01-17.
52-week range$22.36 - $49.10
50-day moving average $41.12
200-day moving average $33.14
Wall St. target price$64.60
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-4.12

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Arcus Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Arcus Biosciences price performance over time

Historical closes compared with the close of $29.07 from 2022-01-20

1 week (2022-01-12) -21.39%
1 month (2021-12-17) -30.12%
3 months (2021-10-21) -17.06%
6 months (2021-07-21) -8.35%
1 year (2021-01-21) -21.54%
2 years (2020-01-21) 190.12%
3 years (2019-01-18) 189.25%
5 years (2017-01-17) N/A

Arcus Biosciences financials

Revenue TTM $37.9 million
Gross profit TTM $-81,831,000
Return on assets TTM -21.13%
Return on equity TTM -51.22%
Profit margin 0%
Book value $7.73
Market capitalisation $2.5 billion

TTM: trailing 12 months

Arcus Biosciences share dividends

We're not expecting Arcus Biosciences to pay a dividend over the next 12 months.

Arcus Biosciences share price volatility

Over the last 12 months, Arcus Biosciences's shares have ranged in value from as little as $22.36 up to $49.1. A popular way to gauge a stock's volatility is its "beta".

RCUS.US volatility(beta: 0.84)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Arcus Biosciences's is 0.837. This would suggest that Arcus Biosciences's shares are less volatile than average (for this exchange).

Arcus Biosciences overview

Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company is also developing Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co. , Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer.

Stocks similar to Arcus Biosciences

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site